FindTrial
Sign In

Efficacy of opioid switching for delirium in patients with cancer: a systematic review

Efficacy of opioid switching for delirium in patients with cancer: a systematic review - Efficacy of opioid switching for delirium in patients with cancer: a systematic review

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000051787
Enrollment
Unknown
Registered
2023-08-02
Start date
2023-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

None listed

Sponsors

Iwao Pharmacy
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. patients with cancer(more than or equal to 80%) 2. patients with delirium 3. Studies examining the efficacy of opioid switching for delirium The study design to be considered for inclusion is as follows: 4. If there were at least two randomized controlled trial (RCT)s, inclusion was completed. 5. If there were less than 2 RCTs, we included non-RCTs or observational studies with control groups. 6. If there were no RCTs/non-RCTs/observational studies with control groups, single-arm observational studies were considered for inclusion.

Exclusion criteria

Exclusion criteria: 1. Duplicate publications 2. Conference proceedings

Design outcomes

Primary

MeasureTime frame
Severity of delirium—

Secondary

MeasureTime frame
Duration of delirium, worsening pain intensity and dyspnea intensity—

Countries

Japan

Contacts

Public ContactKousuke Yamanaka

Iwao Pharmacy Nisseki-mae Mitasu Ise store

kou_y0_0y@yahoo.co.jp0596-65-7555

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026